共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
Marshall E 《Science (New York, N.Y.)》2002,295(5563):2198-2199
4.
二氟沙星肺靶向微球制剂的制备 总被引:1,自引:0,他引:1
以可生物降解的明胶为载体,液体石蜡为油相,Span-80为乳化剂,选择正交设计优化空白明胶微球生产工艺,并考察其理化性质,采用乳化交联法制备二氟沙星肺靶向明胶微球。采用紫外可见分光光度计法,测定微球中二氟沙星的含量。结果表明,优选所制的二氟沙星肺靶向明胶微球形态圆整,表面光滑,平均粒径为8.33μm,粒径分布在5.0~25.0μm的微球达到95.71%,二氟沙星明胶微球包封率为62.43%,载药量为13.71%。采用动态分析法研究体外释药特性,二氟沙星明胶微球在12h处药物释放量达到65%,24h内药物释放量达到71%。制备工艺稳定可行,所得二氟沙星明胶微球具有良好的缓释效果。 相似文献
5.
Brakenhoff RH 《Science (New York, N.Y.)》2011,333(6046):1102-1103
6.
Ransohoff DF 《Science (New York, N.Y.)》2003,299(5613):1679-1680
7.
8.
Reed JC 《Science (New York, N.Y.)》2011,334(6059):1075-1076
9.
10.
Couzin J 《Science (New York, N.Y.)》2005,310(5749):766-767
11.
Couzin J 《Science (New York, N.Y.)》2006,313(5795):1868-1869
12.
目的 研究miR-204在非小细胞肺癌(NSCLC)患者中表达的临床意义及其对SIRT1的靶向调控作用.方法 收集39例原发性NSCLC患者的癌组织和对应癌旁组织标本.实时荧光定量PCR检测组织标本中miR-204的表达水平;并分析其与NSCLC临床病理学特征的关系.将人非小细胞肺癌细胞株A549分别转染miR-204的模拟物或抑制物,CCK-8试剂盒检测细胞的增殖,westem blot检测其潜在靶点基因SIRT1的表达.结果 癌组织中miR-204的表达量为(2.12±1.17),明显低于癌旁组织中的(3.08±1.46),P<0.01.miR-204的表达水平与肿瘤的临床分期以及肿瘤大小有关(均P<0.05),但与患者年龄、性别、吸烟史、分化程度、组织类型及淋巴转移情况无关(P>0.05).A549细胞转染miR-204的抑制物后,细胞的增殖明显增强,SIRT1的表达上调;而转染miR-204模拟物则呈反向变化.结论 miR-204在NSCLC组织中呈低表达,并与患者的临床分期以及肿瘤大小有相关,其可能是通过靶向调控SIRT1而在NSCLC的发生发展中起重要作用. 相似文献
13.
14.
M Bloom 《Science (New York, N.Y.)》1987,235(4785):154-155
15.
CD Greenman 《Science (New York, N.Y.)》2012,337(6090):47-48
16.
Cancer. Germ cell genes and cancer 总被引:1,自引:0,他引:1
17.
Remarkable progress has been achieved in the field of gene therapy over the past decade. The initial excitement in this young field has led to the development of more than 500 gene therapy protocols approved for evaluation in clinical trials. As these clinical trials progress, many obstacles have been identified that investigators in the field will need to overcome. Among the most important areas of investigation in the field of cancer gene therapy are 1) development of novel vectors to improve gene delivery, 2) development of tumor-selective binding to improve specific tumor targeting, and 3) improvement of the therapeutic window to reduce the toxicity of gene therapy administered alone or in combination with conventional agents. The challenge is not to replace current strategies for cancer therapy with gene therapy but to incorporate gene therapy as a more rational, molecularly based approach to increase our therapeutic armamentarium. 相似文献
18.
Marx J 《Science (New York, N.Y.)》2007,315(5816):1211-1213
19.
20.